Metabolic and inflammatory genes in schizophrenia

Psychiatry Research

Volumn 225, Issue 1-2, 2015, Pages 208-211

  Chase, Kayla A ^a   Rosen, Cherise ^a   Gin, Hannah ^a   Bjorkquist, Olivia ^a   Feiner, Benjamin ^a   Marvin, Robert ^a   Conrin, Sean ^a   Sharma, Rajiv P ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Inflammation; Obesity; Schizophrenia

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CHLORPROMAZINE; INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; NEUROLEPTIC AGENT; SREBF1 PROTEIN, HUMAN;

ARTICLE; BODY MASS; C EBP ALPHA GENE; CONTROLLED STUDY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; INFLAMMATION; INFLAMMATORY GENE; MAJOR CLINICAL STUDY; MALE; METABOLIC GENE; OBESITY; OBESOGENIC GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PPARALPHA GENE; PPARGAMMA GENE; SCHIZOPHRENIA; SREBP1 GENE; ADULT; CHEMICALLY INDUCED; ENERGY METABOLISM; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; OVERWEIGHT;

ADULT; ANTIPSYCHOTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEINS; ENERGY METABOLISM; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PPAR ALPHA; PPAR GAMMA; RNA, MESSENGER; SCHIZOPHRENIA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84916620386     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.11.007     Document Type: Article

References (41)

1. Akira S., Isshiki H., Sugita T., Tanabe O., Kinoshita S., Nishio Y., et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO Journal 1990, 9:1897-1906.
2. Alam T., An M.R., Papaconstantinou J. Differential expression of three C/EBP isoforms in multiple tissues during the acute phase response. Journal of Biological Chemistry 1992, 267:5021-5024.
3. Chase K.A., Sharma R.P. Epigenetic developmental programs and adipogenesis: implications for psychotropic induced obesity. Epigenetics: Official Journal of the DNA Methylation Society 2013, 8.
4. Chase K.A., Gavin D.P., Guidotti A., Sharma R.P. Histone methylation at H3K9: evidence for a restrictive epigenome in schizophrenia. Schizophrenia Research 2013, 149:15-20.
5. Chase K.A., Sharma R.P. Nicotine induces chromatin remodelling through decreases in the methyltransferases GLP, G9a, Setdb1 and levels of H3K9me2. International Journal of Neuropsychopharmacology 2012, 1-10.
6. Denner L.A., Rodriguez-Rivera J., Haidacher S.J., Jahrling J.B., Carmical J.R., Hernandez C.M., et al. Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2012, 32:16725-35a.
7. Eder K., Baffy N., Falus A., Fulop A.K. The major inflammatory mediator interleukin-6 and obesity. Inflammation Research: Official Journal of the European Histamine Research Society 2009, 58:727-736.
8. Ferno J., Vik-Mo A.O., Jassim G., Havik B., Berge K., Skrede S., et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009, 203:73-84.
9. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. American Journal of Psychiatry 2010, 167:686-693.
10. Gavin D.P., Kartan S., Chase K.A., Jayaraman S., Sharma R.P. Histone deacetylase inhibitors and candidate gene expression: an in vivo and in vitro approach to studying chromatin remodeling in a clinical population. Journal of Psychiatric Research 2009, 43:870-876.
11. Jayaraman S., Castro M., O'Sullivan M., Bragdon M.J., Holtzman M.J. Resistance to fas-mediated T cell apoptosis in asthma. Journal of Immunology 1999, 162:1717-1722.
12. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
13. Klemettila J.P., Kampman O., Seppala N., Viikki M., Hamalainen M., Moilanen E., et al. Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. European Psychiatry: The Journal of the Association of European Psychiatrists 2014, 14.
14. Koutnikova H., Cock T.A., Watanabe M., Houten S.M., Champy M.F., Dierich A., Auwerx J. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14457-14462.
15. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. Journal of Clinical Investigation, 2011, 121:2111-2117.
16. Mannhalter C., Koizar D., Mitterbauer G. Evaluation of RNA isolation methods and reference genes for RT-PCR analyses of rare target RNA. Clinical Chemistry and Laboratory Medicine 2000, 38:171-177.
17. Mansur R.B., Zugman A., Asevedo E.M., da Cunha G.R., Bressan R.A., Brietzke E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry and Clinical Neurosciences 2012, 66:247-260.
18. Martinez-Gras I., Perez-Nievas B.G., Garcia-Bueno B., Madrigal J.L., Andres-Esteban E., Rodriguez-Jimenez R., et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophrenia Research 2011, 128:15-22.
19. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005, 80:19-32.
20. Meijer K., de Vries M., Al-Lahham S., Bruinenberg M., Weening D., Dijkstra M., et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PloS One 2011, 6.
21. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70:663-671.
22. Na K.S., Jung H.Y., Kim Y.K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2014, 48:277-286.
23. Nose M., Tansella M., Thornicroft G., Schene A., Becker T., Veronese A., et al. Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages?. International Clinical Psychopharmacology 2008, 23:287-290.
24. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. Journal of Biological Chemistry 1998, 273:29279-29282.
25. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
26. Rajkovic N., Zamaklar M., Lalic K., Jotic A., Lukic L., Milicic T., et al. Relationship between obesity, adipocytokines and inflammatory markers in type 2 diabetes: relevance for cardiovascular risk prevention. International Journal of Environmental Research and Public Health 2014, 11:4049-4065.
27. Ramji D.P., Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochemical Journal 2002, 365:561-575.
28. Raschke S., Eckel J. Adipo-myokines: two sides of the same coin-mediators of inflammation and mediators of exercise. Mediators of Inflammation 2013, 320724.
29. Rijcken C.A., Monster T.B., Brouwers J.R., de Jong-van den Berg L.T. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?. Journal of Clinical Psychopharmacology 2003, 23:657-659.
30. Rogowski O., Shapira I., Bassat O.K., Chundadze T., Finn T., Berliner S., Steinvil A. Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional study. Journal of Inflammation 2010, 7:9255-7-9255-35.
31. Salazar M.R., Carbajal H.A., Espeche W.G., Balbin E., Aizpurua M., Marillet A.G., Reaven G.M. Do differences in waist circumference modify the relationships among body mass index, insulin resistance, and related cardiometabolic risk factors in apparently healthy women?. Journal of the American College of Nutrition 2014, 33:32-38.
32. Sarvari A.K., Vereb Z., Uray I.P., Fesus L., Balajthy Z. Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. Biochemical and Biophysical Research Communications 2014, 450:1383-1389.
33. Shapiro H., Lutaty A., Ariel A. Macrophages, meta-inflammation, and immuno-metabolism. Scientific World Journal 2011, 11:2509-2529.
34. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biological Psychiatry 2009, 65:481-488.
35. Song Y.Y., Kim K.R., Park J.Y., Lee S.Y., Kang J.I., Lee E., et al. Associated factors of quality of life in first-episode schizophrenia patients. Psychiatry Investigation 2011, 8:201-206.
36. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002, 3.
37. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. Journal of Clinical Investigation 2006, 116:115-124.
38. Wen X.,Y., Li Y. Liu Opposite action of peroxisome proliferator-activated receptor-gamma in regulating renal inflammation: functional switch by its ligand. Journal of Biological Chemistry 2010, 285:29981-29988.
39. Wertheimer A.I. The defined daily dose system (DDD) for drug utilization review. Hospital Pharmacy 1986, 21. (233-4, 239-41, 258).
40. World Health Organization Physical Status: The use and Interpretation of Anthropometry. Report of a WHO Expert Committee 1995, vol. 854:1-452. World Health Organization Technical Report Series.
41. Xiu M.H., Chen da C., Wang D., Zhang K., Dong A., Tang W., et al. Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology. Journal of Psychiatric Research 2012, 46:1093-1098.